Intraoperative radiotherapy in the multimodality approach to bone and soft tissue cancers.
IORT is a powerful tool for the management of cancer and has been shown to improve local control in the treatment of sarcomas in one prospective, randomized, controlled trial. IORT allows dose escalation in areas where escalation with EBRT would cause potentially excessive acute or late normal tissue toxicity. It has a unique toxicity profile but remains safe and effective when used in appropriately selected patients. In addition, IORT is becoming more widely available at different cancer centers and offers great flexibility in treatment planning for a wide variety of malignancies. As IORT use becomes more common, special care will be required to ensure that it is used by a multidisciplinary team of radiation oncologists and surgeons to ensure the best results for patients.
Ellis
Rodney J
RJ
Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106-6068, USA.
Kim
Edward
E
Kinsella
Timothy J
TJ
Eisenberg
Burton L
BL
D000328:Adult; D001859:Bone Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D001918:Brachytherapy / Q000379:methods; D003131:Combined Modality Therapy; D006801:Humans; D007432:Intraoperative Period; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000209:etiology; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods*; D012509:Sarcoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery